Search

Your search keyword '"Forster, Martin D."' showing total 180 results

Search Constraints

Start Over You searched for: Author "Forster, Martin D." Remove constraint Author: "Forster, Martin D."
180 results on '"Forster, Martin D."'

Search Results

1. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx

2. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

6. The evolution of non-small cell lung cancer metastases in TRACERx

7. The evolution of lung cancer and impact of subclonal selection in TRACERx

8. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

9. The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer.

10. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

11. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

12. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

13. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

14. Multi-institutional, International Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma

15. Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.

16. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy

17. Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

18. Effect of statin treatment on the risk of cancer in patients with heart failure: A target trial emulation study.

20. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

21. Personalising monitoring for chemotherapy patients through predicting deterioration in renal and hepatic function

22. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

24. Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

25. Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

27. Supplementary Methods from BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–Overexpressing Tumors

28. Supplementary Table 3 from BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–Overexpressing Tumors

29. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

30. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

31. Body composition and lung cancer-associated cachexia in TRACERx

32. The evolution of lung cancer and impact of subclonal selection in TRACERx

33. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

34. Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review

35. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

38. International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System

39. Clinical development of new drug-radiotherapy combinations

40. Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma

41. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

44. Predicting Progression Free Survival after Systemic Therapy in Advanced Head and Neck Cancer: Bayesian regression and Model development

45. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

46. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors

50. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Catalog

Books, media, physical & digital resources